Market Place
Sourcing Support
Precision Biosciences Presents At ASGCT 2026 Annual Meeting
28 Apr 2026 //
PHARMIWEB
Precision Bio Expands ELIMINATE-B Trial in Europe
15 Apr 2026 //
PHARMIWEB
Precision Biosciences Gets $7.5M From TG Therapeutics
02 Mar 2026 //
BUSINESSWIRE
Precision BioSciences to Present at 2026 MDA Conference
18 Feb 2026 //
BUSINESSWIRE
Precision BioSciences Outlines 2026 PBGENE-HBV Priorities
12 Jan 2026 //
BUSINESSWIRE
Precision Biosciences Presents ELIMINATE-B Data at HEP-DART 2025
19 Nov 2025 //
BUSINESSWIRE
Precision Biosciences Unveils Phase 1 PBGENE-HBV Data at AASLD
10 Nov 2025 //
BUSINESS WIRE
Precision Biosciences Launches $75M Common Stock Offering
10 Nov 2025 //
BUSINESSWIRE
Precision Biosciences Releases Q3 2025 Financials And Business
03 Nov 2025 //
BUSINESSWIRE
Precision Biosciences Reveals PBGENE-HBV Oral Presentation
14 Oct 2025 //
PHARMIWEB
Precision Bio Publishes ARCUS Study on Gene Insertion Efficiency
09 Oct 2025 //
PHARMIWEB
Precision Biosciences Opens First U.S. Site For ELIMINATE-B Trial
07 Oct 2025 //
PHARMIWEB
Precision Biosciences Presents Poster At World Muscle Society
30 Sep 2025 //
BUSINESSWIRE
Precision Bio Shows Ph 1 ELIMINATE-B HBV Data at Cure Meeting
12 Sep 2025 //
BUSINESSWIRE
Precision BioSciences Shares Phase 1 ELIMINATE-B Trial Data
12 Sep 2025 //
PHARMAWEB
Precision Bio Gets U.S. Patent for PBGENE-HBV, Updates Program
08 Sep 2025 //
PHARMAWEB
Precision BioSciences Reports Phase 1 Safety Data for Hepatitis B
06 Aug 2025 //
BUSINESSWIRE
Precision BioSciences Advances PBGENE-DMD Gene Editing for DMD
16 Jul 2025 //
BUSINESSWIRE
Precision Bio Wins FDA Rare Disease Tag for DMD Gene Therapy
25 Jun 2025 //
BUSINESSWIRE
Precision BioSciences Reports Q1 2025 Results and Business Update
15 May 2025 //
BUSINESSWIRE
Precision BioSciences speeds up PBGENE-DMD development
14 May 2025 //
BUSINESSWIRE
Precision BioSciences to Report Q1 2025 Results on May 15, 2025
08 May 2025 //
BUSINESSWIRE
Precision Bio Unveils PBGENE-HBV Safety Data at EASL
07 May 2025 //
BUSINESSWIRE
Precision BioSciences Announces Presentations at ASGCT Meeting
01 May 2025 //
BUSINESSWIRE
Precision BioSciences Gets FDA Fast Track for PBGENE-HBV
15 Apr 2025 //
BUSINESSWIRE
Precision BioSciences at 24th Annual Needham Virtual Conference
01 Apr 2025 //
BUSINESSWIRE
Precision Bio Shows Preclinical Data On PBGENE-HBV In HBV
20 Mar 2025 //
BUSINESSWIRE
Precision BioSciences Presents Preclinical Data on PBGENE-DMD
19 Mar 2025 //
BUSINESSWIRE
Precision BioSciences Clears FDA Application for PBGENE-HBV
17 Mar 2025 //
BUSINESSWIRE
Precision Bio To Present At MDA Clinical & Scientific Conference
24 Feb 2025 //
BUSINESSWIRE
Precision Bio Shares Initial PBGENE-HBV Data From ELIMINATE-B Trial
19 Feb 2025 //
BUSINESSWIRE
Precision Announces Response In OTC Deficiency Phase 1/2 Trial
09 Jan 2025 //
BUSINESSWIRE
Precision Bio Expands PBGENE-HBV Trial for Chronic Hepatitis B
18 Dec 2024 //
BUSINESSWIRE
Precision BioSciences to Present at November Investor Conferences
21 Nov 2024 //
BUSINESSWIRE
Precision BioSciences to Report Q3 Results on Nov 4, 2024
29 Oct 2024 //
BUSINESSWIRE
Precision BioSciences Hosts Investor Event on PBGENE-HBV Data
28 Oct 2024 //
BUSINESSWIRE
Precision BioSciences Gets 1st Approval For Choronic Hepatitis B
24 Oct 2024 //
BUSINESSWIRE
Precision BioSciences Highlights ARCUS Data At ESGCT Congress
24 Oct 2024 //
BUSINESSWIRE
Precision BioSciences To Present At ESGCT 31st Annual Congress
16 Oct 2024 //
BUSINESSWIRE
Precision Bio To Present At H.C. Wainwright Hepatitis Conference
03 Oct 2024 //
BUSINESSWIRE
Precision BioSciences Submits Applications For PBGENE-HBV Trial
30 Sep 2024 //
BUSINESSWIRE
Precision BioSciences Grants Inducement Awards Under Nasdaq
21 Sep 2024 //
BUSINESSWIRE
Precision BioSciences Strengthens Leadership For PBGENE-HBV Trial
12 Sep 2024 //
BUSINESSWIRE
Precision BioSciences Receives $13M from Imugene Convertible Note Maturity
03 Sep 2024 //
BUSINESSWIRE
TG Therapeutics Gets IND Clearance For Azer-Cel In Multiple Sclerosis
09 Aug 2024 //
BUSINESSWIRE
Precision BioSciences to Participate in Upcoming August Investor Conferences
31 Jul 2024 //
BUSINESSWIRE
Precision Bio: PBGENE-HBV Preclinical Safety Data At EASL
05 Jun 2024 //
BUSINESSWIRE
Precision Bio: EASL 2024 Late-Breaker On Gene Editing
01 May 2024 //
BUSINESSWIRE
Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV
14 Feb 2024 //
BUSINESSWIRE
Precision deals out CAR-T autoimmune rights to TG for $10M
09 Jan 2024 //
FIERCE BIOTECH
Precision Bio Presents Late-Breaking Data Highlighting Safety of PBGENE-HBV
13 Nov 2023 //
BUSINESSWIRE
Precision Hosts Virtual R&D Day Highlighting its Proprietary ARCUS Technology
12 Sep 2023 //
BUSINESSWIRE
Precision BioSciences to Host In Vivo Gene Editing R&D Day on September 12, 2023
31 Aug 2023 //
BUSINESSWIRE
Precision BioSciences Announces Oral Presentation of +ve ARCUS® Gene Editing
22 Jun 2023 //
BUSINESSWIRE
Precision BioSciences to Present at Upcoming June Investor Conferences
05 Jun 2023 //
BUSINESSWIRE
Precision BioSciences Provides Update on Allogeneic CAR T Programs
31 May 2023 //
BUSINESSWIRE
Precision BioSciences to Provide an Update on its Allogeneic CAR T Programs
25 May 2023 //
BUSINESSWIRE
Precision BioSciences Presents Preclinical Data Demonstrating Potential of ARCUS
19 May 2023 //
BUSINESSWIRE
Precision Announces Publication of its Preclinical In Vivo Gene Editing Abstract
12 May 2023 //
BUSINESSWIRE
Precision BioSciences to Report First Quarter 2023 Results on May 9, 2023
02 May 2023 //
BUSINESSWIRE
